FDA Proposes Exclusion of Weight Loss Drugs from Compounding List
The FDA is seeking to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, citing an adequate supply of GLP-1 drugs from major manufacturers.
Editorial Staff
1 min read
Updated 9 days ago
The FDA has announced its intention to exclude certain weight loss medications from its compounding list. Specifically, semaglutide, tirzepatide, and liraglutide are under consideration for removal.
This decision is based on the agency's assessment that there is no shortage of GLP-1 drugs currently available from manufacturers such as Novo Nordisk and Eli Lilly.
The proposed change reflects the FDA's ongoing efforts to ensure that compounded medications are necessary and that there are sufficient alternatives available in the market.